About The Study: In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone was estimated to extend event-free survival by up to 3 years among people with heart failure with mildly reduced or preserved ejection fraction.
Corresponding Author: To contact the corresponding author, Scott D. Solomon, M.D., email ssolomon@rics.bwh.harvard.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.3782)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the Heart Failure Society of America Annual Scientific Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.3782?guestAccessKey=01d86985-5893-4796-8f83-807d6b7a02db&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092724
JAMA Cardiology